One of the two coenzyme forms of vitamin B12 that the body actually uses, sold as an alternative to cyanocobalamin on the argument that it needs no conversion. It is less stable and more expensive.
Methylcobalamin is a perfectly good B12 source with a superiority claim that trials have not supported. Cyanocobalamin is converted efficiently to both active coenzyme forms in healthy people, and comparative studies have not shown better clinical outcomes with the methylated form; some pharmacokinetic work suggests methylcobalamin is actually retained slightly less well. There is a genuine argument for hydroxocobalamin in specific situations, and a theoretical one for methylcobalamin in rare inborn errors of cobalamin metabolism. Neither supports the general marketing, which leans on the same "methylated is better" framing used to sell methylfolate.
Regulation: No Tolerable Upper Intake Level exists for vitamin B12 in any form. Sold as a dietary supplement with no pre-market efficacy review; comparative claims against cyanocobalamin are not assessed before sale.
What the research used
The amounts, forms and durations published trials of Methylcobalamin actually administered.
These are the amounts published trials administered — not a recommendation, and not a dose to copy. Trial participants were screened, supervised and given a characterised preparation. What is in a retail bottle is frequently not what was studied, and the amount that suits one person is not general advice.
Studied for Typical retail supplement
500–5000 µg
Not enough
Sublingual tablet, daily
Far above the 2.4 µg RDA, which is defensible for correcting deficiency through passive diffusion and pointless otherwise. Doses at the top of this range have no evidence of additional benefit.
Studied for Diabetic neuropathy trials
1500 µg
Limited
Daily, divided · 12 weeks–1 year
Mostly small trials from Japan and China with methodological limitations. A trial of high-dose B12 in diabetic neuropathy found no benefit over placebo on nerve conduction.
This is general information about food, not medical advice. It cannot diagnose, treat or replace guidance from a clinician who knows your history.
When it was taken
Each window says whether a trial compared it against an alternative, or whether it is convention and pharmacology. Most timing advice is the second kind.
None of the timings below were directly compared in a trial. They reflect how the research happened to dose, or what the pharmacology implies — which is not the same as a timing being better.
🕐Any time
Not enough
Sublingual products advise holding under the tongue, though comparative studies find swallowed and sublingual B12 raise blood levels similarly. No timing comparison exists.
Timing was not directly compared. This reflects convention or how the compound behaves in the body, not a trial showing this window works better.
The evidence in depth
Best supported: Moderate
What each association actually rests on, and the papers behind it. A rating describes the state of the research, not how promising the supplement sounds. How we rate evidence.
Methylcobalamin corrects B12 deficiency and the fatigue that accompanies it, as any adequate B12 source does. No trial has shown it works better than cyanocobalamin, and in people with normal B12 status neither form improves energy.
Moderate evidence. Several human studies point the same way, with real caveats.
There is not enough evidence that methylcobalamin improves nerve or cognitive outcomes beyond correcting deficiency. Trials in diabetic neuropathy are small and inconsistent, and a well-conducted trial of high-dose B12 in that setting was negative.
Not enough evidence. Not enough human research to say anything useful yet.
Deep research mode adds each paper’s own conclusion and stated limitations.
Things to know
Interactions, contraindications and dose limits, most serious first. Concentrated extracts interact with medication in ways the whole plant does not, so this section carries more weight here than it does on a food page.
Worth knowing
Deficiency still needs diagnosis
Whichever form is used, starting B12 before testing can normalise results and delay identifying pernicious anaemia, coeliac disease or ileal disease. Neurological symptoms with B12 deficiency need prompt medical assessment, not a shelf product.
Worth knowing
Superiority is asserted, not demonstrated
The "no conversion needed" argument is pharmacologically superficial — cyanocobalamin is converted efficiently, and some data suggest methylcobalamin is retained less well. Paying several times more for the methylated form buys a story.
Metformin, proton pump inhibitors, H2 blockers and nitrous oxide affect B12 status regardless of which supplemental form is taken.
Worth knowing
Light-sensitive and less stable
Methylcobalamin degrades faster than cyanocobalamin, particularly in light and in liquid formats, so actual content at the end of shelf life is more variable.